Hormone replacement therapy and the risk of endometrial cancer: A systematic review
The median age at menopause in Europe and North America ranges from 50.1 to 52.8 years [1]. Menopausal symptoms comprise vasomotor symptoms, declining bone mass, vaginal dryness, insomnia and mood disturbances [2]. The mean duration is four years but in about 10% of women, they may continue for up till 12 years [3]. Menopausal hormone therapy is recommended as the most effective treatment for vasomotor symptoms [4]. Options are unopposed estrogen, combined therapy (estrogen and progestogen) or tibolone.
Source: Maturitas - Category: Primary Care Authors: Lea L. Sjögren, Lina S. Mørch, Ellen Løkkegaard Tags: Review article Source Type: research
More News: Cancer | Cancer & Oncology | Endometrial Cancer | Hormonal Therapy | Hormone Replacement Therapy | Hormones | Insomnia | Men | Menopause | Primary Care | Women